Menu

All Items

Page 6 of 8  

First-in-health regulatory changes Kirsten Messmer

Seeking ways to ensure participant safety in first-in-human trials

Kirsten Messmer, Ph.D., R.A.C., principal regulatory affairs specialist, details changes in regulatory guidelines for first-in-human trials.

Read more...
 

Honoring World Alzheimer’s Day Neuroscience Research

Honoring World Alzheimer's Day

Stephen Peroutka, vice president and therapeutic area head in neuroscience, shares his thoughts on the importance and outlook of conducting clinical trials for Alzheimer’s disease.

Read more...
 

Brexit’s potential regulatory impact on the pharmaceutical industry

Brexit's potential regulatory impact on the pharmaceutical industry

Regulatory affairs experts at PPD, Alistair Davidson and Vincenzo Cannizzaro, reflect on how the United Kingdom's departure from the European Union might impact the pharmaceutical industry.

Read more...
 

Major clinical trial reforms underway in China’s regulatory environment thumbnail image

Major clinical trial reforms underway in China's regulatory environment

Bill Wang, director of regulatory affairs, discusses China's regulatory environment in the second-largest pharmaceutical market in the world.

Read more...
 

Charting a new course: Extractable and leachable testing thumbnail image

Charting a new course: Extractable and leachable testing

Derek Wood, an associate director for PPD® Laboratories GMP Lab, discusses the growth of extractables and leachables in the required testing for pharmaceutical products.

Read more...
Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.